sponsored
PatientsVille.com Logo

PatientsVille

Veramyst Medical Research Studies

Up-to-date List of Veramyst Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Veramyst Medical Research Studies

Rank Status Study
1 Unknown  Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma
Condition: Asthma
Interventions: Drug: fluticasone/ salmeterol;   Drug: fluticasone
Outcome Measures: methacholine challenge;   spirometry;   Bmax and Emax;   impulse oscillometry;   mannitol challenge;   serum ECP;   overnight urinary cortisol creatnine clearance
2 Recruiting Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
Condition: Asthma
Interventions: Drug: Fluticasone, Budesonide, Beclomethasone;   Drug: Fluticasone, Beclomethasone, Budesonide;   Drug: Budesonide, Fluticasone, Beclomethasone;   Drug: Budesonide, Beclomethasone, Fluticasone;   Drug: Beclomethasone, Fluticasone, Budesonide;   Drug: Beclomethasone, Budesonide, Fluticasone
Outcome Measures: To show that there is a growth suppressive effect of Pulmicort Flexhaler 180 mcg BID versus Flovent Diskus 100 mcg BID in children with mild asthma.;   To show that there is a growth suppressive effect of QVAR 890 mcg BID versus Flovent Diskus 100 mcg BID in children with mild asthma.
3 Recruiting SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.
Condition: Asthma
Interventions: Drug: ADVAIR 100/50mcg;   Drug: ADVAIR 250/50mcg;   Drug: ADVAIR 500/50mcg;   Drug: FLOVENT 100mcg;   Drug: FLOVENT 250mcg;   Drug: FLOVENT 500mcg
Outcome Measures: Time to first event in the composite endpoint of serious asthma related events (i.e. asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death) over the 6-month treatment period;   Time to first severe asthma exacerbation;   Number and percent of subjects experiencing asthma related hospitalization;   Number and percent of subjects experiencing asthma related endotracheal intubation;   Number and percent of subjects experiencing asthma related endotracheal death;   The number of withdrawals from study treatment due to asthma exacerbation;   The number and percent of rescue-free days (days without use of rescue albuterol/salbutamol (other than pre-exercise)
4 Recruiting A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects
Condition: Asthma
Interventions: Drug: Fluticasone Furoate/Vilanterol;   Drug: Fluticasone Furoate 100 mcg;   Drug: Fluticasone Propionate 250 mcg;   Drug: Fluticasone Propionate 100 mcg;   Drug: Fluticasone Furoate Placebo;   Drug: Fluticasone Propionate Placebo
Outcome Measures: Time to withdrawal due to poorly -controlled (requires step-up) asthma during Period-2;   Proportion of subjects with well-controlled asthma at the end of Period-2;   Mean change from baseline in clinic visit trough FEV1 at the end of Period-2;   Mean change from baseline in daily morning and evening peak expiratory flow (PEF) averaged during Period-2;   Mean change from baseline in the percentage of symptom-free 24-hour periods during Period-2;   Mean change from baseline in the percentage of rescue-free 24-hour periods during Period-2;   Mean change from baseline in Asthma Control Test (ACT) score during Period-2;   Proportion of subjects with ACT score >=20 at the end of the Period-2
5 Not yet recruiting Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution
Condition: Asthma
Interventions: Drug: Fluticasone Propionate Formulation 1;   Drug: Fluticasone Propionate Formulation 2;   Drug: Fluticasone Propionate Formulation 3;   Drug: Fluticasone Propionate Formulation 3*
Outcome Measures: Area Under the Plasma Concentration versus time curve (AUC) for Drug Fluticasone Propionate;   Peak plasma concentration for fluticasone propionate
6 Recruiting 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
Condition: Asthma
Interventions: Drug: ADVAIR 100/50mcg;   Drug: ADVAIR 250/50mcg;   Drug: FLOVENT 100mcg;   Drug: FLOVENT 250mcg
Outcome Measures: Time to first event in the composite endpoint of serious asthma-related outcomes (asthma-related hospitalizations, endotracheal intubations, or deaths) over the 6-month study treatment period;   Time to first asthma exacerbation;   The number and percent of subjects experiencing asthma-related deaths;   The number and percent of subjects experiencing asthma-related endotracheal intubations;   The number and percent of subjects experiencing asthma-related hospitalizations;   The number of withdrawals from study treatment due to asthma exacerbation;   The number and percent of rescue-free days (days without use of rescue albuterol/salbutamol [other than pre-exercise treatment]);   The number and percent of asthma control days
7 Recruiting Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
Condition: Asthma
Interventions: Drug: fluticasone propionate MDPI;   Drug: Fluticasone propionate/salmeterol MDPI;   Drug: Placebo MDPI
Outcome Measures: Change from baseline in trough FEV1 over the 12 week treatment period;   Baseline-adjusted area under the curve for FEV1 AUC0-12 at week 12;   Change from baseline in the weekly average of the daily trough morning PEF over the 12 week treatment period;   Change from baseline in the Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ(S) at final visit;   Change from baseline in Pediatric Asthma Quality of Life Questionnaire with Standardized Activities (PAQLQ(S) at final visit;   Time to meeting alert criteria for worsening asthma;   Time to patient withdrawal due to worsening asthma;   Change from baseline in weekly average of asthma symptoms over weeks 1 to 12;   Change from baseline in weekly average use of albuterol/salbutamol inhalation aerosol over weeks 1 to 12;   Time to 15% and 12% improvement from baseline in post-dose FEV1 at TV1;   Number of participants with adverse events;   Change from baseline in the weekly average of the daily trough evening PEF over the 12 week treatment period
8 Unknown  Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD
Conditions: Chronic Obstructive Pulmonary Disease;   COPD
Interventions: Drug: Combination Fluticasone /Formoterol 12/250 μg;   Drug: Seretide Diskus (salmeterol/fluticasone) 50/250 μg
Outcome Measures: Changes in pre-bronchodilator forced expiratory volume in first second (FEV1);   Changes in forced expiratory volume in first second, without bronchodilator;   Safety descriptive about occurence of adverse events, evaluation of results of clinical/physical examination and laboratory tests results;   Changes in COPD Assessment Test (CAT)
9 Not yet recruiting Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
Condition: Eosinophilic Esophagitis
Interventions: Drug: Oral Viscous Budesonide;   Drug: Fluticasone MDI
Outcome Measures: Histologic effectiveness of viscous budesonide versus fluticasone MDI;   Symptomatic effectiveness of viscous budesonide versus fluticasone MDI;   Symptom recurrence;   Histologic recurrence
10 Recruiting Long-acting Beta Agonist Step Down Study
Condition: Asthma
Interventions: Drug: Fluticasone/Salmeterol Diskus;   Drug: Fluticasone Diskus
Outcome Measures: Treatment Failure;   Pulmonary Function;   Rate of episodes of poor asthma control
11 Recruiting Study of Safety of Foradil in Patients With Persistent Asthma
Condition: Persistent Asthma
Interventions: Drug: Formoterol;   Drug: Fluticasone propionate 100 mcg;   Drug: Fluticasone propionate 250 mcg;   Drug: Fluticasone propionate 500 mcg;   Drug: Placebo
Outcome Measures: Combined serious asthma related events;   Asthma-related hospitalization;   Asthma-related intubation;   Asthma-related deaths;   Rescue medication use;   Symptom and rescue-free days;   Nighttime awakenings;   Asthma control Questionnaire (ACQ - 6) score
12 Unknown  Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo
Conditions: Patients With Active Non-segmental Vitiligo.;   Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%;   Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo
Intervention: Drug: Fluticasone proprionate 0.05% cream
Outcome Measures: Repigmentation of the vitiligo lesions;   Patients satisfaction
13 Unknown  Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease
Condition: Patients With Nasal Polyps
Interventions: Drug: fluticasone furoate;   Other: placebo
Outcome Measures: To evaluate the effect of once daily nasal steroid therapy with fluticasone furoate nasal spray (110 mcg/day) in suppressing nasal polyp-induced symptoms over the course of 16 weeks in patients presenting to the clinic with active nasal polypoid disease.;   To evaluate the efficacy and safety of once daily nasal steroid therapy with fluticasone furoate nasal spray in suppressing the signs of recurrence of nasal polyps over the course of 16 weeks.
14 Not yet recruiting Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
Condition: Asthma
Interventions: Drug: Fluticasone 44 mcg;   Drug: Fluticasone 220 mcg
Outcome Measure: Asthma exacerbations
15 Recruiting Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.
Condition: Mild Persistent Asthma
Interventions: Drug: Flutiform 50/5 ug (2 puffs bid) pMDI;   Drug: Fluticasone 50 ug (2puffs bid) pMDI;   Drug: Beclometasone Autohaler 50 ug (2 puffs bid)
Outcome Measures: To show non-inferiority of flutiform pMDI 50/5 µg (2 puffs bid) versus fluticasone pMDI 50 µg (2 puffs bid) based on the mean lower leg growth rates.;   To compare the safety of flutiform pMDI 50/5 µg (2 puffs bid) versus fluticasone pMDI 50 µg based on overnight urinary free cortisol (corrected for creatinine).
16 Unknown  Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome
Condition: Childhood Obstructive Sleep Apnea Syndrome (OSAS)
Intervention: Drug: fluticasone furoate
Outcome Measures: the number of cells positive for IL-10 and FOXP3 on immunohistochemical staining of adenoid tissues;   the amount of IL-10 and TGF-alpha secreted by adenoid cells after stimulation;   weight of the removed adenoids to be compared between the 2 groups.
17 Recruiting Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients
Conditions: Percentage of Annual Acute Exacerbation;   Quality of Life
Intervention: Drug: Fluticasone/Salmeterol high dose
Outcome Measures: The changes of lung function parameters, including post bronchodilation forced expiratory volume in first second (FEV1) and forced vital capacity (FVC), before and after treatment.;   Annual rate of acute exacerbations
18 Not yet recruiting Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
Condition: Asthma
Interventions: Drug: Fluticasone propionate (Fp) MDPI;   Drug: Fluticasone propionate/Salmeterol (FS) MDPI;   Drug: Placebo MDPI
Outcome Measures: Change from baseline in trough FEV1 over the 12 week treatment period;   Baseline-adjusted area under the curve for FEV1 AUC0-12 at week 12;   Change from baseline in the weekly average of the daily trough morning PEF over the 12 week treatment period;   Change from baseline in the Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ(S) at final visit;   Change from baseline in Pediatric Asthma Quality of Life Questionnaire with Standardized Activities (PAQLQ(S) at final visit;   Time to meeting alert criteria for worsening asthma;   Time to patient withdrawal due to worsening asthma;   Change from baseline in weekly average of asthma symptoms over weeks 1 to 12;   Change from baseline in weekly average use of albuterol/salbutamol inhalation aerosol over weeks 1 to 12;   Time to 15% and 12% improvement from baseline in post-dose FEV1 at TV1;   Number of participants with adverse events;   Change from baseline in the weekly average of the daily trough evening PEF over the 12 week treatment period
19 Not yet recruiting Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Budesonide;   Drug: Fluticasone;   Drug: Indacaterol;   Drug: Salmeterol
Outcome Measures: Change from baseline in trough Forced Expiratory Volume in 1 second;   Change in Health status - mMRC;   Percent use of rescue medications;   Adverse events;   Change from baseline in trough Forced Expiratory Volume in 1 second at week 24;   Change in Health status - SGRQ-C
20 Recruiting Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children
Condition: Dermatitis, Atopic
Interventions: Drug: Fluticasone, cream;   Drug: Placebo,
Outcome Measures: Relapse in Atopic Dermatitis (AD).;   Time to relapse;   Incidence of relapse;   severity of the relapse;   Adverse events and adverse effects;   Therapeutic compliance

These studies may lead to new treatments and are adding insight into Veramyst etiology and treatment.

A major focus of Veramyst research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Veramyst